# Santa Monica College

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/santa-monica-college/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 72.7 |
| Citations | 24,840 |
| City | Santa Monica |
| Country | US |
| Description | Santa Monica College is a research organisation in Santa Monica, US. OpenAlex records 661 works and 24,840 citations for it. 237 researchers list it as their most recent affiliation. |
| Homepage | http://www.smc.edu/Pages/Home.aspx |
| OpenAlex ID | https://openalex.org/I118931453 |
| Researchers | 237 |
| ROR ID | https://ror.org/01cntdd82 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q1033692 |
| Works | 661 |

## University papers

Showing 12 of 26.

- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial](https://scholariq.org/papers/previous-radiotherapy-and-the-clinical-activity-and-toxicity-of-pembrolizumab-in/)
- [Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study](https://scholariq.org/papers/nivolumab-plus-ipilimumab-as-first-line-treatment-for-advanced-non-small-cell/)
- [Bevacizumab for recurrent malignant gliomas](https://scholariq.org/papers/bevacizumab-for-recurrent-malignant-gliomas/)
- [Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-altered-thyroid-cancers/)
- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/osimertinib-with-or-without-chemotherapy-in-i-egfr-i-mutated-advanced-nsclc/)
- [Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/rociletinib-in-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients](https://scholariq.org/papers/circulating-tumour-dna-profiling-reveals-heterogeneity-of-egfr-inhibitor/)

## University researchers

- [Jonathan W. Goldman](https://scholariq.org/researchers/jonathan-w-goldman/)

## University top topics

Showing 8 of 22.

- [Higher Education Research Studies](https://scholariq.org/topics/higher-education-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Wildlife Ecology and Conservation](https://scholariq.org/topics/wildlife-ecology-and-conservation/)
- [Species Distribution and Climate Change](https://scholariq.org/topics/species-distribution-and-climate-change/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Migration, Health and Trauma](https://scholariq.org/topics/migration-health-and-trauma/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.